Rho GTPase inhibitors for refrigerated platelet storage
Award amount
$224,700Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- P2D, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- KX3EAX2JEMV8
- Solicitation number
- PA13-234
- Topic code
- NHLBI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD
- Targeting Latexin for radiation mitigation.
- A first-in-class orally active anti-TNF-alpha inhibitor to treat AD
- A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment
- Activated protein C peptides for radio-mitigation
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
52 SBIR/STTR records share this UEI (2001–2021). Reported award amounts total $21,593,440. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services